SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Oragenics review continues; plans for an IND by end-2026

Oragenics says it is reviewing certain items and remains focused on submitting an Investigational New Drug Application by the end of 2026.

OGEN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.